ACAD ▲ +6.6% - Acadia Pharmaceuticals Inc. $ACAD reported Q3 2026 EPS of $0.31, beating the $0.18 estimate by 72.2%. Revenue of $342.3M beat the $333.0M estimate by 2.8%. 04-NOV-2026 04:20 PM ET